Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:


Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 9,974,845

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,974,845
Title:Combination of vaccination and inhibition of the PD-1 pathway
Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
Inventor(s): Fotin-Mleczek; Mariola (Sindelfingen, DE), Kallen; Karl-Josef (Konigsdorf, DE), Probst; Jochen (Wolfschlugen, DE)
Assignee: CureVac AG (Tubingen, DE)
Application Number:14/769,720
Patent Claims:see list of patent claims

Details for Patent 9,974,845

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2014-12-22 ⤷  Try it Free 2033-02-22
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2017-10-04 ⤷  Try it Free 2033-02-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.